The presence of prostate cancer at biopsy is predicted by a number of genetic variants

Autor: Aniruddh, Kashyap, Wojciech, Kluźniak, Dominika, Wokołorczyk, Adam, Gołąb, Andrzej, Sikorski, Marcin, Słojewski, Bartłomiej, Gliniewicz, Jerzy, Świtała, Tomasz, Borkowski, Andrzej, Borkowski, Andrzej, Antczak, Łukasz, Wojnar, Jacek, Przybyła, Marek, Sosnowski, Bartosz, Małkiewicz, Romuald, Zdrojowy, Paulina, Sikorska-Radek, Józef, Matych, Jacek, Wilkosz, Waldemar, Różański, Jacek, Kiś, Krzysztof, Bar, Piotr, Bryniarski, Andrzej, Paradysz, Konrad, Jersak, Jerzy, Niemirowicz, Piotr, Słupski, Piotr, Jarzemski, Michał, Skrzypczyk, Jakub, Dobruch, Paweł, Domagała, Krzysztof, Piotrowski, Anna, Jakubowska, Jacek, Gronwald, Tomasz, Huzarski, Tomasz, Byrski, Tadeusz, Dębniak, Bohdan, Górski, Bartłomiej, Masojć, Thierry, van de Wetering, Janusz, Menkiszak, Mohammad R, Akbari, Jan, Lubiński, Steven A, Narod, Cezary, Cybulski, Maria Małgorzata, Sąsiadek
Rok vydání: 2013
Předmět:
Zdroj: International Journal of Cancer. 134:1139-1146
ISSN: 1097-0215
0020-7136
Popis: Several single nucleotide polymorphisms (SNPs) have been associated with an elevated risk of prostate cancer risk. It is not established if they are useful in predicting the presence of prostate cancer at biopsy or if they can be used to define a low-risk group of men. In this study, 4,548 men underwent a prostate biopsy because of an elevated prostate specific antigen (PSA; ≥4 ng/mL) or an abnormal digital rectal examination (DRE). All men were genotyped for 11 selected SNPs. The effect of each SNP, alone and in combination, on prostate cancer prevalence was studied. Of 4,548 men: 1,834 (40.3%) were found to have cancer. A positive association with prostate cancer was seen for 5 of 11 SNPs studied (rs1800629, rs1859962, rs1447295, rs4430796, rs11228565). The cancer detection rate rose with the number of SNP risk alleles from 29% for men with no variant to 63% for men who carried seven or more risk alleles (OR = 4.2; p = 0.002). The SNP data did not improve the predictive power of clinical factors (age, PSA and DRE) for detecting prostate cancer (AUC: 0.726 vs. 0.735; p = 0.4). We were unable to define a group of men with a sufficiently low prevalence of prostate cancer that a biopsy might have been avoided. In conclusion, our data do not support the routine use of SNP polymorphisms as an adjunct test to be used on the context of prostate biopsy for Polish men with an abnormal screening test.
Databáze: OpenAIRE